ReviewPharmaceutics2025
A New Approach to the Diagnosis and Treatment of Cardiovascular Diseases.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CADs) have long been considered the domain of the elderly. However, the prevalence of modifiable risk factors has led to their increased diagnosis in younger people. Conventional treatment methods offer a wide range of drugs with different mechanisms of action, but their use brings only limited benefits. Often occurring, persistent adverse effects encourage the abandonment of regular drug administration and thus prevent effective therapy. Methods are sought that allow for targeted, more precise drug delivery that would eliminate their systemic and toxic effects. Therefore, one of the areas of particular interest in the field of cardiovascular diseases is the topic of drug delivery systems based on nanotechnology. We reviewed articles in the PubMed database focused on the latest reports of the use of nanotechnology in the treatment of CADs. Results: Nanoparticles (NCs) bring about many benefits compared to conventional preparations, which results from the possibility of carrying a larger amount of functional cargo and directing the therapy to individual cellular targets, as well as increasing the bioavailability of the transported drug. The introduction of NC to CAD treatment may allow for more effective therapy, but most importantly, it provides an opportunity for faster and more accurate diagnosis of developing disorders at a stage when they do not yet produce symptoms. Nanotechnology, thanks to the enormous variety of designed structures and functions, shows exceptional potential in the diagnosis and treatment of cardiovascular diseases. However, its widespread implementation in clinical practice is a significant challenge. Further research is necessary to provide reliable data on the pharmacokinetics, toxicity, and long-term safety of nanocarriers. The development of industrial methods for the production of nanocarriers with controlled and repeatable physicochemical properties while maintaining economic profitability remains a key challenge. Fulfilling these conditions is necessary for introducing nanotechnology as a standard method in modern cardiovascular medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.